| Title |
Bispecific Antibodies for Cancer Immunotherapy
|
|---|---|
| Published in |
BioDrugs, August 2012
|
| DOI | 10.2165/11530960-000000000-00000 |
| Pubmed ID | |
| Authors |
Dafne Müller, Roland E. Kontermann |
| Abstract |
The concept of using bispecific antibodies to retarget immune effector cells for cancer therapy was conceived more than 20 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe adverse effects and immunogenicity of the bispecific antibodies. A deeper understanding of effector cell biology and especially developments in the field of antibody engineering has led to the generation of new classes of bispecific antibodies capable of circumventing many of these obstacles. Furthermore, new applications were established for bispecific antibodies, such as pre-targeting strategies in radioimmunotherapy or dual targeting approaches in order to improve binding, selectivity, and efficacy. This review summarizes recent progress in the development of bispecific antibodies and describes some new concepts developed for cancer immunotherapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | <1% |
| Germany | 1 | <1% |
| Ireland | 1 | <1% |
| Austria | 1 | <1% |
| Unknown | 113 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 32 | 27% |
| Student > Ph. D. Student | 27 | 23% |
| Student > Bachelor | 15 | 13% |
| Student > Master | 13 | 11% |
| Other | 7 | 6% |
| Other | 14 | 12% |
| Unknown | 9 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 52 | 44% |
| Biochemistry, Genetics and Molecular Biology | 20 | 17% |
| Medicine and Dentistry | 13 | 11% |
| Engineering | 7 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Other | 9 | 8% |
| Unknown | 11 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2024.
All research outputs
#2,864,340
of 25,377,790 outputs
Outputs from BioDrugs
#81
of 746 outputs
Outputs of similar age
#18,020
of 174,033 outputs
Outputs of similar age from BioDrugs
#14
of 257 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 746 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,033 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 257 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.